NCT06582485尚未招募2 期
A Randomized, Placebo-controlled, Double-blind Phase 2b Trial to Assess the Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/mL to Improve Allograft Function in Recipients of Donation After Circulatory Death Kidneys
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 200
- 主要终点
- Delayed Graft Function (DGF)
研究概览
简要总结
Randomized (1:1), placebo controlled, double blind efficacy trial. 200 patients will be followed up for 12 months post transplantation. The primary endpoint will be Delayed Graft Function (DGF) defined as the requirement for dialysis within 7 days post transplantation.
详细描述
The present trial aims to evaluate if iCM012 solution 2 mg/mL can improve short and mid-term allograft function of controlled donation after circulatory death (DCD) kidneys at high risk for Ischemia Reperfusion Injury (IRI) -induced graft dysfunction as assessed by primarily DGF and secondary as estimated glomerular filtration rates (eGFR). The trial will also generate additional efficacy, safety, and exploratory data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 55 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible for use in this trial, an allograft must meet the following criterion:
- •Controlled DCD donors Maastricht category III from 55 to 75 years of age.
- •To be eligible to participate in this trial, a patient must meet all the following criteria:
- •Available, personally signed and dated Informed Consent Form.
- •Male or female chronic kidney disease (CKD) ≥ 18 years of age, on dialysis > 12 months, awaiting their first kidney transplantation.
- •AB0-compatible, negative pre-transplantation Complement Dependent Cytotoxicity (CDC) and/or flow cytometric class I and II crossmatch, or negative virtual class I and II crossmatch, and no pre-existing donor specific antibodies (Mean Fluorescent Intensity under center specific cut-off for negative value).
- •Completed vaccination program according to local standard practice or as deemed relevant by the investigator.
排除标准
- •An allograft that meets any of the following criteria will be excluded from use in this trial:
- •Surgically induced injuries or anatomical vascular variations compromising ex vivo treatment and/or transplantation outcome, as judged by the investigator.
- •DCDs with persistent and significant deterioration of kidney function (30% decrease in eGFR from baseline) and/or on dialysis within two (2) weeks prior to organ procurement and/or anuria > 12 hours before surgery.
- •Extracorporeal membrane oxygenation treatment of the donor
- •A patient who meets any of the following criteria will be excluded from participation in this trial:
- •If not tolerating/eligible for thymoglobulin induction and tacrolimus or Cyclosporine A (CyA)-based maintenance immunosuppressants.
- •Previously undergone any organ and/or cell transplantations.
- •Positive CDC and or flow cytometric class I and/or II crossmatch, and/or positive virtual crossmatch.
- •Highly sensitized patients defined by Panel Reactive Antibody (PRA) level equal or higher than 98%.
- •AB0-incompatible deceased donor kidney transplantation.
- •Pregnant or breast-feeding woman.
- •Woman of child-bearing potential, not using an adequate contraceptive method.
- •Prior participation in a clinical trial with (approved or non-approved) IMPs within 1 month prior to screening for this trial.
- •Prior malignancy diagnosis ≤ 5 years, except for adequately treated basal cell, or squamous cell skin cancer, and carcinoma in situ, or judged as irrelevant by the investigator.
- •Positive result for serum human immunodeficiency virus (HIV), active hepatitis B or C infection in pre-transplantation evaluation.
- •History of severe drug allergy or hypersensitivity, or known hypersensitivity, or intolerance to any of the IMPs or its/their excipients.
- •Concomitant severe conditions requiring treatment and close monitoring, as judged by the investigator.
- •History of any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at increased risk because of participation in the trial, or influence the results or the patient's ability to participate in the trial.
- •Unlikely to comply with trial procedures, restrictions, and requirements (e.g., caused by substance abuse, concurrent medical condition, etc.), as judged by the investigator.
研究组 & 干预措施
Active treatment iCM012 solution 2 mg/mL
Experimental
iCM012 solution 2 mg/mL - 200 mL Investigational Medicinal Product (IMP) solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
干预措施: iCM012 solution 2 mg/mL (Drug)
Placebo
Placebo Comparator
Placebo - 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
干预措施: Placebo (Drug)
结局指标
主要结局
Delayed Graft Function (DGF)
时间窗: First 7 postoperative days.
DGF is defined as the need for dialysis within the first 7 postoperative days.
次要结局
- eGFR over 12 months post transplantation(12 months post transplantation)
- Primary non-function(12 months post transplantation)
- Number of Participants with prolonged DGF(14 days post transplantation)
- Number of Participants with functional DGF(First 7 days post-transplantation)
- Number of dialysis sessions(First 30- and 90-days post-transplantation)
- Changes in Quality of Life(12 months post transplantation)
- Incidence of de novo Human Leukocyte Antigen (HLA) antibodies within 12 months(12 months post transplantation)
- Tubular cell injury assessed by exploratory urinary biomarkers(12 months post transplantation)
- Duration of dialysis sessions (hours)(First 30- and 90-days post-transplantation)
- Incidence of biopsy-proven allograft rejection within 12 months(12 months post transplantation)
研究者
相似试验
尚未招募
2 期
ENA-001 for Post Operative Respiratory Depression (PORD)Respiratory DepressionNCT06137638Enalare Therapeutics Inc.200
已完成
1 期
Immunogenicity and Safety Study of NBP615 in Healthy FemaleCervical CancerNCT04453241SK Bioscience Co., Ltd.200
已完成
1 期
A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal RingHIV InfectionsNCT01144676International Partnership for Microbicides, Inc.45
已完成
4 期
Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary TumorsPainPituitary TumorNCT02351700St. Joseph's Hospital and Medical Center, Phoenix62
招募中
3 期
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical TrialCOVID-19Coronavirus InfectionsNCT05599516National Vaccine and Serum Institute, China16,000